Alnylam has an extensive portfolio of RNAi Intellectual Property (IP) with fundamental, chemistry, delivery, and target patents and patent applications covering the development and commercialization of RNAi therapeutics.
Alnylam’s IP estate includes a large number of issued patents and pending patent applications in the world’s major pharmaceutical markets- United States, European Union, and Japan, along with others throughout the world. They cover synthetic RNA molecules, their synthesis and use, including use as therapeutics, diagnostics and research reagents. We believe these patents and pending applications place Alnylam in the strongest possible position to not only build our company over the long-term and accelerate our efforts to bring life-saving drugs to patients in need, but to enable other companies for advancement of RNAi therapeutics with licenses to our IP estate and associated know-how. This belief has been validated by the progress of Alnylam to date with 11 programs in pre-clinical and clinical development and with over 30 distinct agreements entered into with leading pharmaceutical, biotechnology and research reagent companies.